Press Release

Print Page Print Page        E-mail Page Email Page        RSS Feeds RSS        E-mail Alerts Email Alerts        Financial Tear Sheet Tear Sheet
BIO CEO and Investor Conference to Webcast Alkermes' Corporate Presentation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 8, 2007--Alkermes, Inc. (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live by The Biotechnology Industry Organization (BIO) on Monday, February 12, 2007 at 11:45 a.m. EST. The presentation will be webcast from The Waldorf Astoria Hotel in New York and may be accessed under the investor relation's tab at www.alkermes.com. The presentation will be archived for 14 days.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL® CONSTA® ((risperidone) long-acting injection), the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson; and VIVITROL® (naltrexone for extended-release injectable suspension) the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes. Alkermes' headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

CONTACT: Alkermes, Inc.
Debra Koufos, 617-583-6220
Associate, Corporate Communications

SOURCE: Alkermes, Inc.